Drug Profile

Research programme: cancer therapeutics - Oncotelic Therapeutics

Alternative Names: KGP 207; KGP-156; KGP-18; KGP-94

Latest Information Update: 30 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Baylor University; OXiGENE
Developer Mateon Therapeutics
Class Benzophenones; Small molecules; Thiosemicarbazones
Mechanism of Action Cathepsin K inhibitors; Cathepsin L inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
10 Oct 2016 Mateon Therapeutics has patent protection for cathepsin inhibition in USA
17 Jun 2016 OXiGENE is now called Mateon Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com